The current study examines prevalence of cognitive impairment in four mood disorder samples, using four definitions of impairment. The impact of premorbid IQ on prevalence was examined, and the influence of treatment response.
| INTRODUCTION
Cognitive impairment is a core feature of bipolar disorder and recurrent major depressive disorder (MDD), [1] [2] [3] [4] is associated with difficulties in occupational and interpersonal functioning, 5, 6 and thus has a major impact on depressed individuals' quality of life. First-line antidepressant and psychological treatments have limited beneficial impact on cognitive functioning and deficits persist into recovery. 1, 3, [7] [8] [9] [10] It is therefore crucial to focus not only on clinical outcomes in mood disorder intervention studies, but also on cognitive and functional outcomes.
On the basis of a moderate to large effect size difference in group means between bipolar or MDD patients and healthy controls, it has sometimes been assumed that those with mood disorders may all benefit from interventions specifically to improve cognition. However, studies have suggested that only a percentage of depressed patients (unipolar or bipolar), or euthymic bipolar disorder patients, show significant cognitive impairment, when judged by usual criteria of difference from a normative group mean by number of standard deviations (SDs). [11] [12] [13] This has important implications for treatment and for screening for inclusion in studies that aim to improve cognitive function. Inclusion of a number of depressed individuals with unimpaired cognitive function may wash out any positive effect and result in failed trials. 14, 15 Screening has recently been recommended by a task force of the International Society for Bipolar Disorders. 16 If meaningful screening thresholds can be identified, this may prove beneficial in identifying those who could benefit from specific interventions.
Few studies have examined prevalence rates of cognitive impairment in mood disorder samples. Gualtieri and Morgan 13 examined rates in outpatient samples with bipolar disorder (I and II) and MDD.
Using their conservative criterion of cognitive impairment (two or more cognitive domains impaired > 2 SD below norms for healthy controls), they showed that 20%-30% of those with bipolar disorder or MDD were impaired. Iverson and colleagues 12 studied prevalence rates of cognitive impairment in three different outpatient mood disorder samples (bipolar disorder, unmedicated MDD, and medicated MDD) who completed the same cognitive testing battery as in Gualtieri and Morgan 13 (CNS Vital Signs). Having two or more cognitive domain scores > 1.5 SD below the control norm was suggested as a criterion for identifying significant cognitive impairment, based on low false positive rates (ie, this classified a low percentage of the healthy control participants as impaired). Other approaches to defining cognitive impairment have been proposed outside mood disorder research, including examination of scores on individual cognitive test variables (eg, > 1.5 or 2 SD below healthy controls on two or more cognitive test variables) or using a specified global cognitive composite (eg, > 1.5 or 2 SD on a global cognitive composite). Overall, however, there is little consensus regarding how to define cognitive impairment in mood disorder research or what useful thresholds would be.
Premorbid IQ is an important and often neglected factor that should be taken into account when assessing degree of cognitive impairment. Individuals with a premorbid IQ of ≥ 1 SD below the population mean will, by definition, show results of ≥ 1 SD below the mean on several cognitive tests, and would therefore be defined as being 'cognitively impaired' if a threshold of 1 SD was set. Thus, while some individuals in studies of mood disorders may have illness-related cognitive impairment, others' cognitive impairment may simply be a result of low premorbid cognitive function. In contrast, those with a premorbid IQ of ≥ 1 SD above the population mean are very unlikely to be detected as 'impaired' even if their performance is substantially lower than the level their premorbid IQ would predict. Variability in cognitive performance in mood disorder samples 4, 17 may be, in part, due to these individual differences in mechanisms underlying cognitive impairment. For the above reasons, it would therefore be of use to determine whether measures of premorbid IQ could be used to increase the accuracy of definition of cognitive impairment in mood disorder samples.
The current study aimed to replicate and extend results of studies examining the prevalence of cognitive impairment in mood disorder samples. [11] [12] [13] Findings are presented for four well-defined mood disorder samples: inpatient depression, medication-free outpatient depression, bipolar depression, and euthymic bipolar disorder. Group comparisons with healthy controls for all four samples have been reported previously, [18] [19] [20] [21] but prevalence rates of cognitive impairment, as analysed here, have not been examined. Cognitive impairment will be defined according to the following.
1.
Deviation from controls on predefined domains of cognitive functioning by examining:
(a) the number of domains impaired and (b) the type of domains impaired.
2.
Deviation from controls on a number of individual test variables.
3.
Deviation from controls on a global cognitive composite score.
Further analysis will correct the global cognitive composite scores for premorbid IQ. As far as we are aware, this is the first study in mood disorder samples which specifically determines the impact of premorbid IQ on prevalence of cognitive impairment at an individual level. Previous studies have tended to focus on the protective impact of premorbid IQ or cognitive reserve on cognitive functioning, for example, in bipolar disorder 22 and in depressed individuals receiving electroconvulsive therapy. 23 In two studies (in the inpatient and outpatient depression samples Studies 1 and 2), depressed and healthy control groups underwent treatment and completed follow-up cognitive testing. Thus, the first three analyses above were repeated on follow-up data and assessed in relation to treatment response.
| METHODS
The first two samples presented in this paper completed cognitive assessment at two time-points. To ensure accurate comparison of prevalence rates across time-points, only participants who completed baseline and follow-up cognitive assessments are included in this paper.
All studies used the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) 24 to confirm mood disorder diagnosis. 
| Participants
Fifty-eight inpatients aged between 18 and 60 years, with a primary DSM-IV 28 diagnosis of major depressive episode (MDE; unipolar, n = 50, or bipolar, n = 8), completed both clinical and cognitive assessments. At baseline, 19 participants were unmedicated and were subsequently commenced on an antidepressant medication. Of the remaining participants (n = 39), the dose of their existing antidepressant was increased or they were changed to another antidepressant medication (see Douglas et al. for a detailed report of antidepressant use in the depressed group). No significant differences between medicated and unmedicated patients were observed on any cognitive variables at baseline. At follow-up, all were medicated with an antidepressant, the vast majority with a selective serotonin reuptake inhibitor (SSRI) or serotonin-noradrenaline reuptake inhibitor (SNRI).
Participants were classified according to treatment response at the 6-week follow-up (treatment response ≥50% reduction in MADRS score from baseline to follow-up). The healthy control group consisted of 50 individuals, who were screened for current and past psychiatric conditions using the Mini International Neuropsychiatric Interview (MINI). 29 See Douglas et al. 18 for main cognitive outcome data and additional study information. 
Sixty-nine depressed outpatients, aged between 18 and 65 years, with a DSM-IV defined MDE without psychotic features (single or recurrent major depressive disorder, n = 64, or bipolar II depression, n = 5) completed both cognitive assessments. The depressed sample was psychotropic medication-free for at least 6 weeks prior to recruitment and remained medication-free at follow-up. The definition of treatment response was the same as in Study 1. Fifty-eight healthy control participants (screened using the MINI) completed both cognitive assessments. Cognitive data from this sample have been published previously for baseline 19 and longitudinal findings. 

Sixty-three outpatients with a DSM-IV diagnosis of bipolar disorder (I 
| Cognitive testing
Cognitive tasks used and variables reported across the four samples are displayed in Table 1 . For an explanation of the cognitive tests and testing conditions (eg, time of day and computer software), see original cognitive outcome papers from these studies.
9,18-21
| Statistical analysis
Statistical analyses were conducted using SPSS, version 22-x for
Windows. 31 All cognitive variables and IQ scores were normally distributed. For demographic and clinical characteristics, categorical variables were analysed with χ 2 tests and continuous variables with independent sample t tests.
For each of the four studies, mean scores and SD for cognitive and IQ variables in the healthy control group at baseline were calculated.
Z-scores for depressed and control samples for each of these variables were then calculated using the following equation: (raw score − mean control group )/SD control group . For Studies 1 and 2, both of which had follow-up cognitive data in depressed and control groups, this procedure for calculating Z-scores was repeated using mean scores of the control participants at follow-up. Z-scores were calculated so that a positive Z-score always represented an individual performing more poorly than the mean of the healthy control group, regardless of whether the cognitive variable produced outcomes of accuracy, number of errors or reaction time.
For each study, cognitive variables were grouped to fit into one of Four approaches to defining cognitive impairment were used.
Number of cognitive domains impaired: for ease of comparison
with previous studies in this area, 12, 13 performance was evaluated as the number of cognitive domains in which participants scored below healthy controls by 1, 1.5 and 2 SD. Three SD cut-offs were included because there is no consensus regarding an ideal cut-off, with some studies in mood disorder samples suggesting a conservative cut-off of 2 SD below 'normal' 13 as reflecting meaningful cognitive impairment, and other studies suggesting less conservative cut-offs of 1 or 1.5 SD.
12,32,33
Percentage of depressed participants impaired in each cognitive
domain: in order to examine whether specific cognitive domains had higher prevalence rates of impairment, the percentage of participants impaired at 1, 1.5 and 2 SD cut-offs on each cognitive domain was calculated for depressed participants and healthy controls.
3. Global cognitive composite: the prevalence of cognitive impairment when using the global cognitive composite was assessed in depressed and healthy control groups, at 1, 1.5 and 2 SD cut-offs. T A B L E 2 Demographic characteristics of mood disorder and healthy control samples The above four approaches were repeated with follow-up data for Studies 1 and 2 for treatment responders, non-responders and healthy controls. Statistical comparisons between responders and non-responders were conducted using Mann-Whitney U tests (for approaches 1 and 2 above) or χ 2 tests (for approaches 3 and 4 above).
Change in prevalence rates (comparison of single values or spread of rates, depending on the approach) of cognitive impairment in healthy control groups from baseline to follow-up was assessed using
McNemar tests or paired t tests (Wilcoxon signed rank test).
The influence of premorbid IQ (from National Adult Reading Test
[NART] 34 scores) on cognitive performance was taken into account by re-analysing the global cognitive composite scores from each study.
For each individual, the Z-score for premorbid IQ was subtracted from the Z-score for the global cognitive composite. For example, if an individual was 1 SD worse than healthy controls on both their premorbid IQ and overall cognitive performance, their corrected score of 0 would reflect this balance. However, if an individual performed 1 SD worse than healthy controls on overall cognitive performance but had an IQ of 0.5 SD better than healthy controls, the cognitive score was corrected by reducing it to 1.5 SD worse than controls to reflect this discrepancy. The percentage of depressed individuals who were impaired at 1, 1.5 and 2 SD cut-offs on the IQ-corrected global cognitive composite was then calculated for each study.
| RESULTS
Demographic details are presented in Table 2 . No significant differences between depressed and healthy control groups were found for gender, age, number of years of formal education, or premorbid IQ (NART). Table 3 presents clinical data for the four samples. Missing scores on measures in Table 3 are due to differences in clinical data collected between studies. The inpatient depression sample was severely depressed at baseline assessment, with an average MADRS score of
Scores on the MADRS and HDRS-17 in outpatient depressed
and bipolar depressed samples indicated moderate depression severity, and the euthymic bipolar sample (who were excluded if they were depressed) scored in the normal range on the HDRS-17.
| Baseline prevalence of cognitive impairment
Prevalence rates of cognitive impairment, using four approaches to define impairment, are presented in Table 4 . Regarding the number of cognitive domains impaired (first approach), most healthy control participants were not impaired on any cognitive domains at 1.5 SD (82%-94%) and 2 SD (92%-97%) cut-offs. Participants with mood disorders, particularly the inpatient depressed sample, were generally impaired on a greater number of cognitive domains than healthy controls. For example, at the 1.5 SD cut-off, 37.5% of the inpatient depression T Prevalence of impairment on a global cognitive composite (third approach) was low in healthy control groups from all studies (eg, impaired by > 1.5 SD = 0%-1.9%; impaired by >2 SD, all = 0%). For patient groups, prevalence rates at the 2 SD cut-off were also low (0%-7.5%). At the 1.5 SD cut-off, 18.9% of the inpatient depression sample were impaired, compared with only 2.9% of the outpatient depression sample. Both bipolar samples had similar rates of cognitive impairment at the 1.5 SD cut-off (12.5%-14.3%).
Prevalence rates obtained using the final method of defining cognitive impairment, which calculated the percentage of participants impaired on at least two individual test variables, are shown in Table 4 , and discussed further below.
| Prevalence of cognitive impairment corrected for premorbid IQ
Global cognitive composite scores, corrected for premorbid IQ, for each mood disorder sample are presented in Figure 1 . Prevalence rates of cognitive impairment for the 1.5 SD cut-off increased for 
T A B L E 4 (Continued)
F I G U R E 1 Percentage of mood disorder samples impaired at the 1.5 standard deviation (SD) cut-off on global cognitive composite after correction for premorbid IQ. BD, bipolar disorder. *Chi-square test, χ 2 = 4.1, P = .04 Table 5 presents the same four approaches to determining prevalence rates of cognitive impairment using follow-up data. In Study 1, prevalence of cognitive impairment in the domain of psychomotor speed was significantly greater in treatment non-responders compared with treatment responders at follow-up (eg, 1.5 SD = 0.0% vs 18.2%;
| Prevalence of cognitive impairment in relation to treatment response
2 SD = 0.0% vs 3.0%: P = .01). No significant differences between treatment responders and non-responders were found for any other comparisons using the four approaches to classifying cognitive impairment (all P ≥ .05) in either inpatient or outpatient depression samples.
The prevalence of cognitive impairment in the healthy control samples between baseline and follow-up did not differ significantly using any approach (all P ≥ .1).
| DISCUSSION
| Prevalence of cognitive impairment in mood disorders
Due to differences in cognitive testing batteries and demographic characteristics, the current study cannot accurately compare preva- research is that scores on one or more individual test variables should be at least 1 SD below the mean for their age. 35 Of course, 16% of healthy individuals will score > 1 SD below the norm on a single cognitive test, 12 and thus, it was decided that scores on at least two different cognitive tests should be impaired for the classification used
here. This definition has been used recently in a clinical trial of a cognitive remediation intervention in bipolar disorder, in which patients were screened for objective cognitive impairment. 36 However, this definition of impairment appeared to be influenced by the number of tests in the cognitive testing battery; that is, in the study that included the most cognitive tests (Study 4), a high percentage of patients (78%) and, more unusually, healthy controls (49%) were categorized as impaired. In comparison, rates of impairment in other healthy control samples ranged from 13% to 26% at the same cut-off. This approach may be of more use across studies in similar clinical populations using identical cognitive testing batteries.
The method of determining the number of cognitive domains impaired (with no focus on the type of cognitive domain) has been examined previously in depressed samples. Cut-offs of 1.67 and 2 SD, on two or more cognitive domains, have been suggested since this Fisher's exact test (no statistical value available).
Bold indicates P-value of less than .05.
T A B L E 5 (Continued)
gives low false positive rates (ie, low rates for healthy control groups).
Using the 2 SD cut-off, Gualtieri and Morgan 13 found that 21% of their MDD sample and 30% of their bipolar disorder sample were impaired on at least two domains, compared with 3.6% of healthy controls. In the current sample, using the same criteria, a lower rate of impairment was found; ranging from 4.4% (outpatient depression sample) to 14.3% (inpatient depression sample). These lower rates are of note since the inpatient sample in the current study was likely to be much more severely depressed than the outpatient samples from Gualtieri and Morgan's study (although mood rating scales were not used in that study). The cognitive testing battery completed by the inpatient depressed sample in the current study was brief because of the severity of depression. This briefness may have come at the expense of being sensitive to cognitive impairment and also of having a reliable representation of the specified cognitive do-
main. Lower prevalence of cognitive impairment in comparison with
Gualtieri and Morgan's study in our three outpatient samples (Studies 2-4) may be explained by our samples being less severely depressed.
This study did not directly compare matched samples of patients with bipolar disorder and unipolar MDD. For example, the samples consisting of patients who were in a mood episode (Studies 1-3) were not matched for severity or treatment. Therefore, rates of impairment in bipolar depression cannot be compared usefully with those in unipolar depression. We also note that in Studies 1 and 2, the small percentage of patients with bipolar depression (Study 1 = 13.8% bipolar depression; Study 2 = 7.2%) meant that a separate analysis to compare rates of impairment in bipolar and unipolar depressed patients was not warranted. In these two studies, we have previously reported results of re-analyses of main cognitive measures that omitted bipolar patients, with these re-analyses not changing results significantly in terms of P-values or effect size differences.
18,19
A less commonly used approach for defining cognitive impairment is to examine rates of impairment for each cognitive domain. In the current study, large variability in rates of impairment was seen between cognitive domains. The domain of verbal learning and memory produced the highest rates of impairment in three of the samples (17%-36% impairment at 1.5 SD cut-off); however, variability between rates of impairment in other cognitive domains made it difficult to determine meaningful patterns. Cullen et al., 11 in their review of euthymic bipolar samples, found substantial variability in rates of impairment within cognitive domains, which they attributed to small sample sizes and mixed study designs. Regardless of these mixed findings, the profile of impairment across cognitive domains is important to consider. Significant impairment on a single cognitive domain may still impact on general functioning in tasks related to this domain, and if looking only at global cognitive functioning, marked impairment on one domain may be diluted to the extent that impairment is no longer evident.
This dilution of any marked impairment on a single domain was indeed observed when using a global cognitive composite score from each cognitive testing battery to define impairment. This approach resulted in generally lower rates of cognitive impairment (range over the four samples at the 1.5 SD cut-off = 1.6%-18.9%) compared with other approaches, which, as suggested previously, was likely due to a flattening out of variability in areas of strengths and weaknesses in cognitive domains for each individual. An advantage of this approach, however, was that it was simplest to calculate and interpret prevalence rates of impairment.
Global cognitive composite data illustrated a potential methodological weakness of all four studies reported in the current paper.
While the distributions of cognitive scores in control participants did not depart significantly from normal, in a perfectly normal distribution, the rate of impairment in the healthy control groups should have been 6.7%. The actual result in the combined control group was 1%. This skew may have arisen from the fact that people with a perception that they have cognitive impairment are unlikely to volunteer to take part in a study involving cognitive testing, thereby giving rise to an attenuated tail in the distribution.
The current paper reported prevalence of cognitive impairment based on pre-selected, mathematical cut-off points that have been 
| Changes in rates of cognitive impairment with treatment
In the inpatient depression sample, there was a difference in rates of impairment between responders and non-responders only when examining the domain of psychomotor speed. No treatment responders were impaired in this domain at 1.5 and 2 SD cut-offs at followup testing, while 18.2% and 3% of non-responders were impaired at these cut-offs, respectively. In the outpatient depression sample, after 16 weeks of weekly psychological therapy, there was no evidence of rates of cognitive impairment reducing in treatment responders compared with non-responders, in keeping with an analysis based on group means.
9
These findings generally support studies suggesting limited effects of treatment, even when otherwise successful, on cognitive function. 1, [7] [8] [9] [10] Reduced rates of impairment in psychomotor speed in the inpatient depression sample should be interpreted with caution since it was an isolated finding in this analysis. However, it is in accord with a previous study in an inpatient sample 38 and previous reviews have suggested that psychomotor speed may be the domain most likely to improve with successful treatment. This analysis emphasizes the importance of taking premorbid IQ into account, particularly when screening for cognitive impairment prior to commencing cognitive remediation interventions. Such wide range in types of antidepressant medications prescribed meant that sub-analyses to examine differential effects of medications on cognitive function were not warranted. Of note, however, is that baseline analysis comparing cognitive performances of medicated and non-medicated patients did not produce any significant differences. In addition, a recent large-scale RCT (n = 1008) found no evidence that three types of antidepressant medication (escitalopram, venlafaxine or sertraline) differentially improved cognitive impairment over time.
| Limitations
10
Limitations of using a word-reading test, such as the NART, as a measure of premorbid cognitive functioning should be noted.
Evidence suggests the NART to be a reliable and valid proxy measure of general IQ, as well as being relatively resistant to the effects of psychiatric disorders. 42 However, at a more conceptual level, using NART performance as an estimate of premorbid IQ, and then generalizing this to performance on a broad range of cognitive tests (eg, memory and executive function) may be overly simplistic.
Incorporation of demographic variables (eg, age, education level and socioeconomic status) into a formula to estimate premorbid cognitive functioning may be more comprehensive but, to date, research has typically focused on such formulae to predict general IQ, rather than premorbid cognitive ability. Finally, it is possible that scores on the NART are affected by a phenomenon of lower cognitive performance in those susceptible to mood disorder. This could be related either to a trait biological effect 43 or to adversity associated with parental mood disorder.
| IMPLICATIONS AND CONCLUSIONS
The traditional presentation of cognitive data as group means of depressed vs control groups (or treatment responders vs nonresponders) does not give a good indication of the numbers of participants in the sample with clinically significant cognitive impairment.
Determining which individuals have significant cognitive impairment is particularly important in treatment trials which will involve screening to improve cognitive outcomes. 16 The specific definition of impairment used for screening depends to some degree on the type of cognitive remediation intervention used. For example, if a cognitive remediation intervention is to be tailored to an individual's cognitive profile, then a definition that incorporates performance on each cognitive domain would be required. If a drug treatment known to have a side-effect burden was being trialed, then a particularly stringent definition of cognitive impairment would be most appropriate since this would only be used in individuals likely to gain very significant cognitive benefit. Thus, this current paper cannot provide a single recommendation for a method of screening for cognitive impairment. It has, however, highlighted the substantial variability in rates of cognitive impairment based on the definitions used and gives an indication of the percentages of different clinical groups who are likely to be classified as having impairment using these different definitions. This paper has also identified definitions of cognitive impairment that are less useful in mood disorder studies; the use of a definition based on a number of individual test results is less useful unless a set battery is used consistently. Furthermore, the study has highlighted the importance of taking into account premorbid IQ, particularly in individuals with severe depression.
Alongside the direct implications of findings from this paper is the question of who should be remediated in mood disorder samples.
Typically, treatment decisions for mood symptoms are individualized to the patient. For example, if patients have a history of trauma, they are more likely to respond to therapy rather than medication. 44 The same may be true for cognitive remediation, in that if patients have cognitive impairment, they are more likely to respond than those who are functioning well. Certainly, research indicates that individuals with the most severe cognitive impairment receive the greatest benefit from interventions aimed at improving cognitive outcomes. 45 As in all clinical trials, there is a difficult balance between the imperative of the clinical trial-to produce a positive result, often achieved by selecting the most impaired patients-and the ability to develop treatments that may be effective across a range of impairment and are generalizable.
Impairments of 0.5-1 SD in key cognitive functions may still be disabling but statistically less likely to show differences between an investigational treatment and placebo.
A related issue is that in MDD, psychological treatments based on cognitive activation may have positive effects on mood and cognition and therefore be potentially beneficial in individuals with milder cognitive impairment. 46, 47 Allowing only those with serious cognitive impairment to partake in cognitive remediation interventions thus means that the majority of individuals with mood disorders will not have the opportunity to experience the activating effects on mood of repetitive cognitive training. The purpose of any proposed cognitive intervention, whether to activate or remediate, is important to consider prior to conducting screening procedures.
